Introduction to platinib and what diseases it treats

Platinib, brand name Pujihua, is an oral, once-daily, potent and highly selectiveRET inhibitor. As the first selective RET inhibitor approved for marketing in China, platinib can effectively inhibit the proliferation of cells expressing RET gene mutations, bringing new breakthroughs in the field of cancer treatment.

Platinib is mainly used to treat certain types of cancer. Specifically, it is suitable for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for transfection rearrangement (RET) gene fusion. These patients often have received platinum-containing chemotherapy, but their disease has not been effectively controlled. The emergence of platinib provides a new treatment option for these patients, which is expected to prolong survival and improve quality of life.

In addition, platinib is also indicated for the treatment of adults and pediatric patients 12 years and older with advanced or metastatic RET-mutated medullary thyroid carcinoma (MTC) who require systemic therapy. Platinib has also shown good therapeutic effects in adults and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic treatment and are refractory to radioactive iodine.

The drug was developed byBlueprint Medicines and exclusively developed and commercialized by CStone Pharmaceuticals in Greater China. Its safety and effectiveness have been verified by multiple clinical studies, bringing new hope to many cancer patients.

In general, platinib plays an important role in the anti-cancer field due to its high selectivity and potency. It not only provides a new treatment method for patients with RET gene fusion-positive non-small cell lung cancer, but also brings good news to patients with RET-mutant medullary thyroid cancer and refractory thyroid cancer. Through continued treatment, platinib is expected to help patients delay disease progression and improve quality of life.